Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Fact-checkers and HIV advocates break down the president’s State of the Union boasts.
A new lawsuit accuses the imprisoned hedge funder of blocking generic rivals of an AIDS-related drug.
“This is excellent news for all children living with HIV.”
The FDA has found a probable cancer-causing contaminant in generic drugs shipped from abroad––most recently, Zantac (ranitidine).
At the center of the lawsuit is Teva Pharmaceutical, slated to sell a generic version of the HIV prevention pill PrEP next year.
The head of the Food and Drug Administration cited a long commute and time away from family as reasons to step down.
U.S. activists unveil a national action plan to #BreakThePatent. It points out that taxpayers funded the research behind Truvada as PrEP.
Stocks of drug companies are rising—and that’s not a good sign for consumers.
The FDA commissioner wants drugmakers to “end the shenanigans.”
However, Gilead Sciences, the brand-name manufacturer of Truvada, insists a generic version “will not be immediately available.”
Scott Gottlieb has said he wants lower costs and faster drug approvals.
New HCV treatment boasts over 90 percent cure rates, costs $84,000 for in the United States.
The Irish pharmaceutical company Actavis has agreed to buy out rival New York City-based Forest Laboratories.
Bill proposed as a way to close gaps in care and get cheaper meds to the people who need them.
India’s Patent Office has ended exclusive rights to a cancer drug made by German manufacturer Bayer
To help people with HIV who cannot afford their antiretroviral (ARV) medications, former President Bill Clinton has proposed that the U.S...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.